Successful pregnancy outcome in women with bad obstetric history and recurrent fetal loss due to thrombophilia: Effect of unfractionated heparin and low-molecular weight heparin

Clinical and Applied Thrombosis/Hemostasis

Volumn 14, Issue 2, 2008, Pages 174-179

  Ghosh, Kanjaksha ^a   Shetty, Shrimati ^a   Vora, Sonal ^a   Salvi, Vinita ^a  

^a KEM HOSPITAL   (India)

Author keywords

Low molecular weight heparin; Recurrent spontaneous abortion; Unfractionated heparin

Indexed keywords

CORTICOSTEROID; HEPARIN; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY;

ABORTION; ADULT; ANTICOAGULATION; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; FEMALE; FETUS WASTAGE; FOLLOW UP; HUMAN; LABORATORY TEST; LIVE BIRTH; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOPHILIA; TREATMENT OUTCOME;

ABORTION, HABITUAL; ADULT; ANTICOAGULANTS; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY OUTCOME; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 40549098963     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029607306400     Document Type: Article

References (24)

1. Brenner B., Sarig G., Weiner Z., Younis J., Blumenfeld Z., Lanir N. Thrombophilic polymorphisms are common in women with fetal loss without apparent causes. Thromb Haemost. 1999 ; 82: 6-9.
2. Kupferminc MJ, Elder A., Steinman N., et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 1999 ; 340: 9-13.
3. Many A., Schreber L., Rosner S., Lessing JB, Eldor A., Kupferminc MJ Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia. Obstet Gynecol. 2001 ; 98: 1041-1044.
4. Gris JC, Quere I., Monpeyroux F., et al. Case control study of the frequency of thrombophilic disorders in couples with late fetal loss and no thrombotic antecedent- The Nimes Obstetricians and Hematologists Study 5 (NOHA5). Thromb Haemost. 1999 ; 81: 891-899.
5. Empson M., Lessere M., Creig J., Scott J. Recurrent pregnancy loss with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005 ; 2 :CD002859.
6. Sanson BJ, Lensing AW, Prins MH, et al. Safety of low molecular weight heparin in pregnancy: a systematic review. Thromb Haemost. 1999 ; 81: 668-672.
7. Exner T., Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioral patterns. Br J Haematol. 1978 ; 40: 143-151.
8. Thiagarajan P., Pengo V., Shapiro SS The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood. 1986 ; 68: 869-874.
9. Sambrook J., Fritsch EF, Manniatis T. Molecular Cloning: A Laboratory Manual. New York, NY: Cold Spring Harbor Laboratory Press ; 1989.
10. Arruda VR, Annichino-Bizzacchi JM, Costa FF, Reitsma PH Factor V Leiden (FVQ506) is common Brazilian population. Am J Hematol. 1995 ; 49: 242-243.
11. Poort SR, Rosendaal R., Leitsma PH, Bertina RM A common genetic variation in the 3′ translocated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996 ; 88: 3698-3703.
12. Abbate R., Sardi I., Pepe G., et al. The high prevalence of thermolabile 5-10 methylinetetrahydrofolate reductase risk for coronary artery disease (CAD). Thromb Haemost. 1998 ; 79: 727-738.
13. Akar N., Gokdemir R., Ozel D., Akar E. EPCR gene exon III, 23 bp insertion mutation in Turkish paediatric thrombotic patients. Thromb Haemost. 2002 ; 88: 1068-1069.
14. Morange PE, Henry M., Tregouet D., et al. The A-844 G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriers. Arterioscler Thromb Vasc Biol. 2000 ; 20: 1387-1391.
15. Rai R., Cohen H., Dave M., Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid.antibodies). BMJ. 1997 ; 314: 253-257.
16. Heilman L., von Tempelhoff GF, Pollow K. Antiphospholipid syndrome in obstetrics. Clin Appl Thromb Hemost. 2003 ; 9: 143-150.
17. Bick RL Recurrent miscarriage syndrome and infertility due to blood coagulation protein/platelet defects: a review and update. Clin Appl Thromb Hemost. 2005 ; 11: 1-13.
18. Heilmann L., Schneider DM, von Tempelhoff GF Antithrombotic therapy in high risk pregnancy. Hematol Oncol Clin North Am. 2000 ; 14: 1133-1150.
19. Branch DW, Silver RM, Blackwell N., Reading JC, Scott JR Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of Utah experience. Obstet Gynaecol. 1992 ; 80: 614-620.
20. Derksen RH, Khamashta MA, Brauch DW Obstetric antiphospholipid syndrome. Arthritis Rheum. 2004 ; 50: 1028-1139.
21. Hawkins D., Evans J. Minimising the risk of heparin induced osteoporosis during pregnancy. Expert Opin Drug Saf. 2005 ; 4: 583-590.
22. Carlin AJ, Farquharson RJ, Quenby SM, Topping J., Fraser WD Prospective observational study of bone mineral density during pregnancy: low molecular weight heparin versus control. Hum Reprod. 2004 ; 19: 2211-2214.
23. Warkentin TE, Levine MN, Hirsh J., et al. Heparin induced thrombocytopenia in patients treated with LMWH or UFH. N Engl J Med. 1995 ; 332: 1330-1335.
24. Brenner B. Clinical management of thrombophilia related placental vascular complications. Blood. 2004 ; 103: 4003-4009.